Update on Dry Eye Disease
Author:
- 21 June 2022
- journal article
- letter
- Published by American Medical Association (AMA) in JAMA
- Vol. 327 (23) , 2355-2356
Abstract
To the Editor The recent JAMA Insights article1 about the pathophysiology, diagnosis, and treatment of dry eye disease provided clear and concise information for practicing clinicians. However, other approaches for treatment of dry eye disease could have been mentioned, such as OC-01 (varenicline solution) nasal spray. In the primary phase 3 trial2 (ONSET-2) that included 758 patients with dry eye disease, treatment with OC-01 (varenicline solution) nasal spray for 4 weeks improved tear production and patient-reported symptoms compared with vehicle (control) nasal spray. In October 2021, this drug was approved by the US Food and Drug Administration for treatment of dry eye disease.Keywords
This publication has 4 references indexed in Scilit:
- Efficacy and Safety of OC-01 (Varenicline Solution) Nasal Spray on Signs and Symptoms of Dry Eye DiseaseOphthalmology, 2022
- Dry Eye DiseaseJAMA, 2022
- A Randomized Clinical Study (SEECASE) to Assess Efficacy, Safety, and Tolerability of NOV03 for Treatment of Dry Eye DiseaseCornea, 2020
- Advances in the diagnosis and treatment of dry eyeProgress in Retinal and Eye Research, 2020